A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > REGULATORY
REGULATORY
- Prioritized Flu Vaccinations for Elderly from October 1, Others Asked to Wait until October 26
September 14, 2020
- Japan to Officially Sign Up for COVAX Pact; Govt to Hammer Out Payment on Sept. 15
September 14, 2020
- Komeito Prods Govt to Tap State Coffers for Coronavirus Vaccinations
September 11, 2020
- MHLW Calls for Smooth Supply of Flu Shots as It Anticipates Surging Demand
September 11, 2020
- Japan to Steadily Collect Info on AstraZeneca Trial Pause: Minister
September 11, 2020
- Japan to Require Pledges from Troubled Generic Makers to Skip Next Listing Round If Supply Issues Occur Again
September 10, 2020
- Label Revisions Ordered for Plaquenil, Relumina
September 10, 2020
- Japan Scrambles to Collect Info on AstraZeneca Vaccine Trial Pause, Sticks to 2021 H1 Immunization Goal
September 10, 2020
- MHLW Erases Hydroxychloroquine, 4 Other Drugs from COVID-19 Treatment Guide
September 10, 2020
- Bid-Rigging Scandal by Wholesalers “Interferes with” Development of Pharma Industry: MHLW Bureau Chief
September 9, 2020
- Japan to Earmark 671.4 Billion Yen to Secure Coronavirus Vaccines, Anticipating Final Agreements with 3 Companies
September 9, 2020
- 1st COVID-19 Case Confirmed at NIHS
September 9, 2020
- Coronavirus Vaccines “Will Need to Be Evaluated More Carefully than Ordinary Medicines”: Top MD Bureaucrat
September 8, 2020
- Sakigake Status Should Not Be Granted to Novartis Products until It Takes Prevention Measures for Approval Delay: Pharma Bureau Chief
September 8, 2020
- Rakuten Medical’s Sakigake-Designated Photoimmunotherapy Clears MHLW Panel
September 8, 2020
- Medical Professionals to Be Prioritized in COVID-19 Vaccination: Govt Panel
September 8, 2020
- PMDA Reviewing Safety Risks for Takecab, 2 Other Drugs
September 7, 2020
- Former Pharma Bureau Chief Tarumi to Assume Vice Health Minister on September 14
September 7, 2020
- PMDA Presents Views on Efficacy, Safety Evaluations for Domestic Development of COVID-19 Vaccines
September 4, 2020
- Govt Holds 1st Meeting of Regenerative Medicine/Cell Therapy Panel, Eyeing Proposals in FY2021
September 4, 2020
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…